Across Europe the pharmaceutical industry has committed to disclose the payments that it has made to healthcare professionals (HCPs) and organizations (HCOs) through adoption of the European Pharmaceutical Industry's HCP/HCO Disclosure Code.
The very best clinical practice requires input and expertise from many groups: clinicians; patient organisations; academics; healthcare organisations; and those that discover and manufacture new medicines and medical technology. Collaboration between all of these important experts results in three main benefits:
- Making new medicines possible in the first place;
- Providing vital health education to ensure that medicines are used appropriately; and
- Capturing real life insights into current treatments and understanding unmet medical needs.
It's important these relationships are managed transparently to help demonstrate that the over-riding objective is to keep patients at the centre of our collective efforts. At Lilly, we value our relationship with HCPs and HCOs and fully support the European Federation of Pharmaceutical Industries and Association's (EFPIA's) commitment to publishing the details of payments and transfers of value made to them through annual disclosure reports. Examples of transfers of value may include a grant to an HCO, a consultancy fee for speaking, travel expenses, or registration fees to attend a medical education congress. Details are reported either by individual HCP or HCO or in an aggregate manner, based on individual or organizational choice in accordance with respective country privacy laws. Reports are published annually and are available for three years with the first year of disclosure occurring in 2016 for payments and transfers of value to HCPs and HCOs made in 2015.
About the Code
The EFPIA Disclosure Code requires all EFPIA member companies (those within and outside of the European Union) to disclose payments and transfers of value to HCPs and HCOs.
Data privacy requires companies to acquire consent from the HCP for the individual disclosure of his/her name with associated transfers of value. If the HCP does not grant his/her consent for the individual disclosure, Lilly will report the associated payments and transfers of value in aggregate, under an unnamed category. Consent must also be collected from an HCO in some countries.
Below are links to our reports for each country publishing data in accordance with the EFPIA Disclosure Code and methodological notes that describe Lilly's methods for meeting the requirements outlined by each country (countries begin reporting in May with all countries reporting by June 30). Please note that in some countries data from all EFPIA member companies are published centrally and in these cases the link will take you to a third party website. Lilly provides this information in accordance with the EFPIA Disclosure Code and in the spirit of greater transparency (click to read our letter of certification for 2018, 2019, and 2020).
|HCP/HCO Disclosure Report||Methodological Notes|
|Bosnia and Herzegovina|
* There has been no reportable Transfers of Value to HCPs nor HCOs in this country during this year.